## Mark E Prince

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2931773/publications.pdf

Version: 2024-02-01

72 papers

2,445 citations

29
h-index

214527 47 g-index

72 all docs 72 docs citations

72 times ranked  $\begin{array}{c} 4031 \\ \text{citing authors} \end{array}$ 

#	Article	IF	CITATIONS
1	The medial sural artery perforator flap: An underutilized flap in oral cavity reconstruction. Oral Oncology, 2022, 124, 105417.	0.8	2
2	Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2022, 28, 350-359.	3.2	38
3	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials. Clinical and Translational Radiation Oncology, 2022, 33, 30-36.	0.9	O
4	Facilitating Automated Data Analytics Through Structured Head and Neck Oncology Tumor Board Documentation. JCO Clinical Cancer Informatics, 2022, 6, e2100168.	1.0	0
5	Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel ⟨scp⟩Bclâ€xL⟨/scp⟩ inhibitor. Head and Neck, 2022, , .	0.9	2
6	Prioritizing Diversity in Otolaryngology–Head and Neck Surgery: Starting a Conversation. Otolaryngology - Head and Neck Surgery, 2021, 164, 229-233.	1.1	40
7	Osteotomized folded scapular tip free flap for complex midfacial reconstruction. , 2021, 8, .		1
8	Revisiting pedicled latissimus dorsi flaps in head and neck reconstruction: contrasting shoulder morbities across mysofascial flaps. Plastic and Aesthetic Research, 2021, 2021, .	0.2	4
9	<scp>Longâ€term</scp> neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. Head and Neck, 2021, 43, 1621-1628.	0.9	2
10	Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer. Oncologist, 2021, 26, 676-684.	1.9	8
11	Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget, 2021, 12, 1214-1229.	0.8	37
12	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. Oral Oncology, 2021, 121, 105332.	0.8	15
13	Lateral border and scapular tip free flaps: Old school versus new school. Head and Neck, 2021, , .	0.9	4
14	Predictors and Prevalence of Nodal Disease in Salvage Oropharyngectomy. Annals of Surgical Oncology, 2020, 27, 451-457.	0.7	3
15	Impact of extrinsic tongue muscle invasion on stage migration in AJCC 8th edition staging of oral cavity carcinoma. Oral Oncology, 2020, 110, 104888.	0.8	1
16	Using self-collection HPV testing to increase engagement in cervical cancer screening programs in rural Guatemala: a longitudinal analysis. BMC Public Health, 2020, 20, 1406.	1.2	7
17	Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 2085-2093.	0.8	3
18	Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy. Journal of Neuro-Oncology, 2020, 147, 25-35.	1.4	11

#	Article	IF	CITATIONS
19	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. Head and Neck, 2020, 42, 1728-1737.	0.9	6
20	Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma. Head and Neck, 2019, 41, 423-428.	0.9	11
21	Wire bristle foreign body: Never in the same place twice. SAGE Open Medical Case Reports, 2019, 7, 2050313X1985344.	0.2	2
22	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 857-864.	0.9	28
23	HPV self-sampling acceptability in rural and indigenous communities in Guatemala: a cross-sectional study. BMJ Open, 2019, 9, e029158.	0.8	28
24	Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 213-220.	2.0	36
25	IRX-2 therapy with PD-L1 blockade in immunocompetent animal model Journal of Clinical Oncology, 2019, 37, e14149-e14149.	0.8	2
26	Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncology, 2018, 77, 83-89.	0.8	53
27	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. Cell Reports, 2018, 25, 1332-1345.e5.	2.9	66
28	The Spider Limb Positioner in subscapular system free flaps. Oral Oncology, 2018, 85, 24-28.	0.8	16
29	Comparison of Outcomes in Medical Therapy vs Surgical Intervention of Esophageal Foreign Bodies. Otolaryngology - Head and Neck Surgery, 2018, 159, 656-661.	1.1	5
30	Pediatric Clival Chordoma: A Case Series and Rationale for Next-Generation Sequencing. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.4	0
31	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 355.	1.2	32
32	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	0.9	34
33	Positron emission tomography–CT prediction of occult nodal metastasis in recurrent laryngeal cancer. Head and Neck, 2017, 39, 980-987.	0.9	17
34	Survival and Margin Status in Head and Neck Radiation-Induced Sarcomas and De Novo Sarcomas. Otolaryngology - Head and Neck Surgery, 2017, 157, 252-259.	1.1	14
35	Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngology - Head and Neck Surgery, 2017, 157, 625-630.	1.1	5
36	Preoperative Tracheostomy Is Associated with Poor Diseaseâ€Free Survival in Recurrent Laryngeal Cancer. Otolaryngology - Head and Neck Surgery, 2017, 157, 432-438.	1.1	18

#	Article	IF	CITATIONS
37	Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncology, 2017, 68, 5-8.	0.8	67
38	Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. Head and Neck, 2017, 39, 2512-2518.	0.9	35
39	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngology - Head and Neck Surgery, 2017, 157, 995-997.	1.1	7
40	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. Laryngoscope, 2016, 126, E184-90.	1.1	12
41	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. Oral Oncology, 2016, 60, 32-40.	0.8	30
42	Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 1074-1084.	0.9	259
43	Occult Nodal Disease Prevalence and Distribution in Recurrent Laryngeal Cancer Requiring Salvage Laryngectomy. Otolaryngology - Head and Neck Surgery, 2016, 154, 473-479.	1.1	45
44	IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. Neoplasia, 2016, 18, 273-281.	2.3	23
45	Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Clinical Cancer Research, 2016, 22, 4735-4745.	3.2	107
46	Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular Cancer Research, 2016, 14, 941-952.	1.5	43
47	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. Radiotherapy and Oncology, 2016, 120, 81-86.	0.3	50
48	Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncology, 2016, 61, 159-165.	0.8	60
49	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. Laryngoscope, 2016, 126, E292-E299.	1.1	20
50	Oral Cancer and Cancer Stem Cells: Relevance to Oral Cancer Risk Factors, Premalignant Lesions, and Treatment. Current Oral Health Reports, 2016, 3, 65-73.	0.5	5
51	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. Head and Neck, 2016, 38, 184-190.	0.9	35
52	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs, 2016, 34, 481-489.	1.2	30
53	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 313.	1.2	11
54	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. Oral Oncology, 2016, 54, 68-74.	0.8	15

#	Article	IF	Citations
55	Matted nodes: High distantâ€metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus–related oropharyngeal cancer. Head and Neck, 2016, 38, E805-14.	0.9	39
56	Human papillomavirus infection and biomarkers in sinonasal inverted papillomas: clinical significance and molecular mechanisms. International Forum of Allergy and Rhinology, 2015, 5, 701-707.	1.5	40
57	The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. Cancers, 2015, 7, 2094-2109.	1.7	19
58	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
59	Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget, 2015, 6, 71-84.	0.8	66
60	Sinonasal Inverted Papilloma: Prognostic Factors with Emphasis on Resection Margins. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 140-146.	0.4	9
61	Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy. Head and Neck, 2014, 36, 1589-1595.	0.9	34
62	Efficacy of Induction Selection Chemotherapy vs Primary Surgery for Patients With Advanced Oral Cavity Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 134.	1.2	33
63	Oral epithelial stem cellsâ€"Implications in normal development and cancer metastasis. Experimental Cell Research, 2014, 325, 111-129.	1.2	41
64	Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio. Translational Oncology, 2014, 7, 479-483.	1.7	7
65	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 2014, 50, 513-519.	0.8	62
66	Restoration of the Orbital Aesthetic Subunit with the Thoracodorsal Artery System of Flaps in Patients Undergoing Radiation Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, 279-285.	0.4	7
67	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 1320.	1.2	93
68	Thoracodorsal Artery Scapular Tip Autogenous Transplant. JAMA Otolaryngology, 2010, 136, 958.	1.5	57
69	Microsurgical Reconstruction of the Head and Neck. Archives of Facial Plastic Surgery, 2010, 12, 209-209.	0.8	0
70	Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer. JAMA Otolaryngology, 2008, 134, 363.	1.5	46
71	Targeting Apoptosis to Overcome Cisplatin Resistance: A Translational Study in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S106-S108.	0.4	27
72	Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm. Journal of Clinical Oncology, 2006, 24, 593-598.	0.8	240